Clinical trial
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A…
NCT00428220 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00428220 |
|---|---|
| Title | A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study. |
| Official title | An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Study type | Interventional |
| Conditions | Metastatic Breast Cancer, Advanced Breast Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Renal Cell Cancer, Non-Small Cell Lung Cancer, Thyroid Cancer, Advanced/Metastatic Non-Small Cell Lung Cancer, Advanced Gastric Cancer, Gastrointestinal Stromal Tumor, Hepatocellular Carcinoma and 2 more |
| Intervention type | Drug |
| Interventions | sunitinib |
| Enrollment | 223 |
| Start date | Jul 1, 2007 |
| Primary completion | Aug 1, 2014 |
| Completion | Sep 1, 2014 |
| First posted | Jan 29, 2007 |
| Last update posted | Jun 27, 2019 |
| Countries | Argentina, Australia, Belgium, Brazil, Canada, Colombia, France, Germany, Hong Kong, Mexico, Philippines, Singapore and 5 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: